$RHHBY News Article - Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
https://marketwirenews.com/news-releases/gene...40130.html